Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs that address severe medical conditions, including cancer and chronic inflammatory diseases. The company's product pipeline primarily includes elesclomol, an oxidative stress inducer, which is in Phase III clinical trial for the treatment of metastatic melanoma, and about to enter Phase II clinical trial for the treatment of additional cancers. It also develops STA-9090, an Hsp90 inhibitor, which is in the Phase I clinical trial for the treatment of cancer; and STA-9584, which is in preclinical development stage for the treatment of cancer. In addition, the company offers Apilimod (STA-5326), which is in Phase IIa clinical trial in patients with rheumatoid arthritis, as well as sponsors a Phase IIa clinical trial in patients with gastrointestinal manifestations of common variable immunodeficiency. Further, it provides Oral CRAC ion channel inhibitor program, which is in the lead optimization stage for the treatment of autoimmune diseases. The company has a partnership agreement with Glaxosmithkline for the development and commercialization of elesclomol; and a strategic alliance with Roche Holding AG to discover, develop, and commercialize small-molecule drugs targeting a novel family of ion channels. Synta Pharmaceuticals Corp. was founded in 2000 and is based in Lexington, Mass.
CLINICAL TRIALS (10 of them):
Outstanding Shares: 136.44M
Institutional Investors hold 49.2% of outstanding shares
Huge institutional names own SNTA including:
Royal Bank of Canada
Swiss National Bank
...and many more!